In considering the effects of cilostazol treatment on some metabolic disorders, vasculo-angiogenic biomarkers, and PCSK9 concentrations, cilostazol use might have a prognostic impact in patients with PAD or at a high risk of CVD. This evidence concerns the gene PCSK9 and peripheral arterial disease.